EP1360496A4 - METHODS AND REAGENTS FOR RAPID AND EFFICIENT ISOLATION OF CIRCULATING CANCER CELLS - Google Patents

METHODS AND REAGENTS FOR RAPID AND EFFICIENT ISOLATION OF CIRCULATING CANCER CELLS

Info

Publication number
EP1360496A4
EP1360496A4 EP02806645A EP02806645A EP1360496A4 EP 1360496 A4 EP1360496 A4 EP 1360496A4 EP 02806645 A EP02806645 A EP 02806645A EP 02806645 A EP02806645 A EP 02806645A EP 1360496 A4 EP1360496 A4 EP 1360496A4
Authority
EP
European Patent Office
Prior art keywords
reagents
rapid
methods
cancer cells
circulating cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02806645A
Other languages
German (de)
French (fr)
Other versions
EP1360496A1 (en
Inventor
Leon W M M Terstappen
Galla Chandra Rao
Shawn Mark O'hara
Paul A Liberti
Steven Gross
Gerald Doyle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunivest Corp
Original Assignee
Immunivest Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunivest Corp filed Critical Immunivest Corp
Publication of EP1360496A1 publication Critical patent/EP1360496A1/en
Publication of EP1360496A4 publication Critical patent/EP1360496A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y25/00Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/549Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic with antigen or antibody entrapped within the carrier
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G01N33/561Immunoelectrophoresis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • HELECTRICITY
    • H01ELECTRIC ELEMENTS
    • H01FMAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F1/00Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
    • H01F1/0036Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
    • H01F1/0045Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
    • H01F1/0054Coated nanoparticles, e.g. nanoparticles coated with organic surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Electrochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Power Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP02806645A 2001-02-16 2002-02-19 METHODS AND REAGENTS FOR RAPID AND EFFICIENT ISOLATION OF CIRCULATING CANCER CELLS Withdrawn EP1360496A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US26885901P 2001-02-16 2001-02-16
US268859P 2001-02-16
US26927001P 2001-02-20 2001-02-20
US26927101P 2001-02-20 2001-02-20
US269271P 2001-02-20
US269270P 2001-02-20
PCT/US2002/005233 WO2003065042A1 (en) 2001-02-16 2002-02-19 Methods and reagents for the rapid and efficient isolation of circulating cancer cells

Publications (2)

Publication Number Publication Date
EP1360496A1 EP1360496A1 (en) 2003-11-12
EP1360496A4 true EP1360496A4 (en) 2005-03-09

Family

ID=27670560

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02806645A Withdrawn EP1360496A4 (en) 2001-02-16 2002-02-19 METHODS AND REAGENTS FOR RAPID AND EFFICIENT ISOLATION OF CIRCULATING CANCER CELLS

Country Status (8)

Country Link
EP (1) EP1360496A4 (en)
JP (1) JP2005516217A (en)
KR (1) KR20030080002A (en)
AU (2) AU2002306561A2 (en)
BR (1) BR0207290A (en)
CA (1) CA2438112A1 (en)
IL (1) IL157256A0 (en)
WO (1) WO2003065042A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
EP1597353B1 (en) 2003-02-27 2010-11-24 Veridex, LLC CIRCULATING TUMOR CELLS (CTC's): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS
CA2539108A1 (en) * 2003-09-18 2005-03-31 Immunivest Corporation Operator independent programmable sample preparation and analysis system
WO2005085845A1 (en) * 2004-03-03 2005-09-15 Universidad De Salamanca Method for the multidimensional detection of aberrant phenotypes in neoplastic cells to be used to monitor minimal disease levels using flow cytometry
CA2582713A1 (en) * 2004-10-06 2006-04-20 Wellstat Biologics Corporation Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment
US7595380B2 (en) * 2005-04-27 2009-09-29 Tripath Imaging, Inc. Monoclonal antibodies and methods for their use in the detection of cervical disease
CN1772303A (en) * 2005-10-25 2006-05-17 朱宏 Nanometer magnetic powder-antibody targeting medicine for magneto thermical threrapy of malignant tumor
US7842465B2 (en) * 2006-01-17 2010-11-30 Palo Alto Research Center Incorporated Immunocytostaining methods for enhanced dye ratio discrimination in rare event detection
ATE483972T1 (en) * 2006-02-16 2010-10-15 Ventana Med Syst Inc REAGENTS AND METHODS FOR CANCER PROGNOSIS AND PATHOLOGICAL GRADING
JP2009529880A (en) * 2006-03-13 2009-08-27 ベリデックス・エルエルシー Primary cell proliferation
EP2008102A4 (en) * 2006-04-18 2009-07-08 Wellstat Biologics Corp Detection of proteins from circulating neoplastic cells
MX2008013331A (en) * 2006-04-18 2008-11-10 Wellstat Biologics Corp DETECTION OF STEROID RECEPTORS IN CIRCULATING CARCINOMA CELLS AND TREATMENT.
MX2008015425A (en) * 2006-06-02 2008-12-12 Pfizer Prod Inc Circulating tumor cell assay.
CN101583722A (en) 2006-07-14 2009-11-18 阿维瓦生物科学股份有限公司 Methods and compositions for detecting rare cells from a biological sample
US8110101B2 (en) 2007-08-30 2012-02-07 Veridex, Llc Method and apparatus for imaging target components in a biological sample using permanent magnets
US7828968B2 (en) 2007-08-30 2010-11-09 Veridex, Llc Method and apparatus for imaging target components in a biological sample using permanent magnets
RU2389024C1 (en) * 2008-12-02 2010-05-10 Александр Валентинович Шишкин Method of study of cells by means of immunological biochip
US20120004289A1 (en) * 2009-03-06 2012-01-05 The Johns Hopkins University Annexin a11 and associated genes as biomarkers for cancer
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
AU2010229924B2 (en) 2009-03-24 2016-07-21 Plus Therapeutics Inc. Devices and methods of cell capture and analysis
DE102009047146B4 (en) * 2009-11-25 2012-07-19 Ulrich Pachmann A method for predicting the response of a tumor disease to a therapeutic intervention
EP2583101B1 (en) 2010-06-17 2015-09-16 Koninklijke Philips N.V. Multi epitope assay
EP2591363B1 (en) * 2010-07-07 2017-09-20 The Regents Of The University Of Michigan Diagnosis and treatment of breast cancer
US20120252038A1 (en) * 2011-04-01 2012-10-04 Chianese David A Steroid receptor assays
EP2728354B1 (en) * 2011-06-29 2018-06-13 LSI Medience Corporation Non-specific reaction inhibitor, method for inhibiting non-specific reaction, and kit
BR112014012882A2 (en) 2011-11-29 2017-06-13 Genentech Inc method, antibody, polynucleotide, host cell, hybridoma cell line, antibody use and kit
US20150044224A1 (en) * 2012-03-02 2015-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Materials and methods for differential treatment of cancer
CN102914650B (en) * 2012-06-14 2014-11-05 北京大成生物工程有限公司 Quantitative detection kit for neuronspecific enolase (NSE) and preparation method and application thereof
EP2964672B1 (en) 2013-03-05 2019-10-09 Board of Regents, The University of Texas System Specific detection tool for mesenchymal and epithelial-mesenchymal transformed circulating tumor cells
CN104561246B (en) * 2013-10-18 2018-06-15 深圳先进技术研究院 The method and kit of the detection signal amplification of circulating cancer cells in blood
JP6582486B2 (en) * 2015-03-27 2019-10-02 コニカミノルタ株式会社 Method for detecting rare cells in blood
KR101723072B1 (en) 2016-12-29 2017-04-05 주식회사 지노바이오 Cell separation system
WO2017142190A1 (en) 2016-02-18 2017-08-24 주식회사 지노바이오 Cell separation chip and system
KR101723082B1 (en) 2016-12-29 2017-04-05 주식회사 지노바이오 Cell Separator
US10426424B2 (en) 2017-11-21 2019-10-01 General Electric Company System and method for generating and performing imaging protocol simulations
CN110669823B (en) * 2018-07-03 2022-05-24 中国医学科学院肿瘤医院 ctDNA library construction and sequencing data analysis method for simultaneously detecting multiple liver cancer common mutations
JP6935883B2 (en) * 2018-07-13 2021-09-15 五稜化薬株式会社 Pretreatment method for fluorescence image diagnosis
US20240295549A1 (en) * 2020-08-07 2024-09-05 Vital Biosciences Inc. Multiplexed analyte detection
CN114958748B (en) * 2022-04-24 2024-02-13 东北大学 Nanomagnetic affinity materials for efficient capture and non-destructive release of circulating tumor cells
CN118741012B (en) * 2024-09-02 2024-12-24 浙江芯劢微电子股份有限公司 Video signal filtering method, circuit and computer readable storage medium

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999041613A1 (en) * 1998-02-12 1999-08-19 Immunivest Methods and reagents for the rapid and efficient isolation of circulating cancer cells
WO1999058978A2 (en) * 1998-05-11 1999-11-18 The University Of Nottingham Tumour markers
US5993829A (en) * 1987-04-23 1999-11-30 Bystryn; Jean-Claude Anti-cancer vaccine
WO2000047998A1 (en) * 1999-02-10 2000-08-17 Cell Works Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512657A (en) * 1988-12-12 1996-04-30 Bainbridge Sciences, Inc. Detection of complexes which include basement membrane components as diagnostic of cancer and other diseases
JPH07509251A (en) * 1992-07-22 1995-10-12 ザ トラスティーズ オブ プリンストン ユニバーシティ p53 vaccine
US5545527A (en) * 1994-07-08 1996-08-13 Visible Genetics Inc. Method for testing for mutations in DNA from a patient sample
US6190870B1 (en) * 1995-08-28 2001-02-20 Amcell Corporation Efficient enrichment and detection of disseminated tumor cells
WO2000020029A1 (en) * 1998-10-05 2000-04-13 Genzyme Corporation Genes differentially expressed in cancer cells to design cancer vaccines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993829A (en) * 1987-04-23 1999-11-30 Bystryn; Jean-Claude Anti-cancer vaccine
WO1999041613A1 (en) * 1998-02-12 1999-08-19 Immunivest Methods and reagents for the rapid and efficient isolation of circulating cancer cells
WO1999058978A2 (en) * 1998-05-11 1999-11-18 The University Of Nottingham Tumour markers
WO2000047998A1 (en) * 1999-02-10 2000-08-17 Cell Works Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
E.RACILA ET AL: "Detection and characterization of carcinoma cells in the blood", PROCEEDING OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 95, 1 April 1998 (1998-04-01) - 1998, pages 4589 - 4594, XP002313397 *
See also references of WO03065042A1 *

Also Published As

Publication number Publication date
BR0207290A (en) 2005-06-07
WO2003065042A1 (en) 2003-08-07
AU2008249153A1 (en) 2008-12-11
IL157256A0 (en) 2004-02-19
CA2438112A1 (en) 2003-08-07
KR20030080002A (en) 2003-10-10
AU2002306561A2 (en) 2003-09-02
JP2005516217A (en) 2005-06-02
AU2008249153B2 (en) 2012-05-10
EP1360496A1 (en) 2003-11-12

Similar Documents

Publication Publication Date Title
EP1360496A4 (en) METHODS AND REAGENTS FOR RAPID AND EFFICIENT ISOLATION OF CIRCULATING CANCER CELLS
EP1434887A4 (en) METHOD OF ISOLATING CELLS AND USE THEREOF
NO990110D0 (en) Prefabricated shower module and method of shower design
DK1003532T3 (en) Intestinal cell absorption of minerals
EA200000274A3 (en) METHODS OF OBTAINING AND INTERMEDIATE CONNECTIONS FOR OBTAINING ANTI-TRAY COMPOUNDS
ID25792A (en) ANTIBODIES OF HUMAN CD40
ID20191A (en) DESIGN AND DEVELOPMENT OF SOLID ELECTRONITE ION REACTORS FOR CONSTRUCTION
NO20011303L (en) Methods for nucleic acid propagation and sequencing
DK1148875T3 (en) Methods and compositions for increasing the number of white blood cells
IL154159A0 (en) Directed differentiation of ebryonic cells
EP1546719A4 (en) ISOLATION AND IDENTIFICATION OF T CELLS
EP1389970A4 (en) COMPOSITIONS AND METHODS FOR DOUBLE TARGETING OF VIRAL INFECTIONS AND CANCER CELLS
GB9808264D0 (en) Biochemical devices and their methods of manufacture
GB0416516D0 (en) Method of transducing es cells
NO20024879L (en) Method of detecting cells
FI20011940L (en) Flotation mechanism and cell
AU2409602A (en) Method of testing anticancer agent-sensitivity of tumor cells
AU1744600A (en) Detection of t cell stimulating tumor antigens
AU2002309989A1 (en) Directed evolution of protein in mammalian cells
EP1566639A4 (en) CANCER CELL EXAMINATION METHOD AND REAGENT THEREFOR
EP1282723A4 (en) METHODS OF DETECTING CANCER CELLS AND SCREENING ANTICANCER AGENTS
AU2003260131A8 (en) Assays for the detection of biliverdin in birds and reptiles
EP1303287A4 (en) MHC OUREXPRIMES PEPTIDES ON PROSTATE CANCER CELLS AND METHODS OF USE
GB2361699B (en) Analysis of complex biological mixtures
AU2003200334A1 (en) Methods and reagents for the rapid and efficient isolation of circulating cancer cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DOYLE, GERALD

Inventor name: GROSS, STEVEN

Inventor name: LIBERTI, PAUL, A.

Inventor name: O'HARA, SHAWN, MARK

Inventor name: RAO, GALLA, CHANDRA

Inventor name: TERSTAPPEN, LEON, W., M., M.

17P Request for examination filed

Effective date: 20040112

A4 Supplementary search report drawn up and despatched

Effective date: 20050124

17Q First examination report despatched

Effective date: 20050531

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080619